'BRCAness' and its implications for platinum action in gynecologic cancer.

  title={'BRCAness' and its implications for platinum action in gynecologic cancer.},
  author={Franco M. Muggia and Tamar Safra},
  journal={Anticancer research},
  volume={34 2},
Gynecological carcinomas are major therapeutic targets of platinum-containing regimens. They may be particularly susceptible to these agents if their origins are related to hereditary breast cancer (BRCA) mutations; this implicates defective DNA repair secondary to inherited alterations in BRCA function. The concept of 'BRCAness' was introduced by Ashworth and colleagues in order to identify phenotypic changes in sporadic cancer that would lead to analogous treatment susceptibility. In fact… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 17 extracted citations


Publications referenced by this paper.
Showing 1-10 of 93 references

BRCA 1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel : a Gynecologic Oncology Group Study

  • JL Lesnock, KM Darcy, +6 authors TC Krivak
  • Br J Cancer
  • 2013

Similar Papers

Loading similar papers…